![Medical News Asia | Powered by ['mediPr]](https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png)
Coronavirus Disease 2019 (COVID-19) emerged in late 2019 and later transformed into a pandemic. Since the United States Food and Drug Administration (FDA) granted Emergency Use Authorisation for COVID-19 vaccines.
SARS-CoV-2 virus is the causative agent of Coronavirus Disease 2019 (COVID-19) and has infected many over the past two-and-a-half years, including healthy people and those with underlying co-morbidities such as the immunocompromised. Following the administration of COVID-19 vaccines from late 2020 onwards, severe and critical COVID-19 outcomes decreased by over 60%.
Severe COVID-19 infection does not only bring about patient distress, but also increases public health expenditure in supportive devices such as ventilators. It is necessary to minimise the risk of COVID-19 infection in cancer patients, considering COVID-19 waves are likely to recur regularly and they are the high-risk groups. Personal hygiene measures and COVID-19 vaccination have been demonstrated to be efficacious and should be recommended to cancer patients for lowering the likelihood of hospitalisation, ICU admission and mortality.
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.
Human papillomavirus (HPV) can cause cervical cancer, anogenital cancers and head and neck cancers if long-lasting infections are triggered by high-risk HPV strains, accounting for the great burden of HPV-related cancers worldwide with an estimated incidence in 570,000 women and 600,000 men each year.
Lung cancer is one of the leading cancers in Hong Kong, accounting for 26.4% of cancer mortality in 2018. Approximately 80% of the lung cancers are non-small cell lung cancer (NSCLC).
Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer. The most frequent genetic mutation harboured in lung adenocarcinomas occurs in the epidermal growth factor receptor (EGFR), accounting for 40-55% in Asian patients.
There is no excerpt because this is a protected post.
The liver cancer trials presented at American Society of Clinical Oncology (ASCO) 2021 were mainly focused on first-line treatments, with a few trials in the neoadjuvant, adjuvant and second-line setting.